GRAPHITE BIO INC (GRPH) Stock Price, Quote, News and Overview
NASDAQ:GRPH - Nasdaq - US38870X1046 - Common Stock - Currency: USD
GRPH Quote, Performance and Key Statistics
3.18
-0.09 (-2.75%)
The current stock price of GRPH is 3.18 USD. In the past month the price increased by 4.95%. In the past year, price increased by 29.8%.
GRPH Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About GRPH
Company Profile
Graphite Bio, Inc. operates as a clinical-stage gene editing company. The company is headquartered in South San Francisco, California and currently employs 120 full-time employees. The company went IPO on 2021-06-25. The firm has a gene editing platform that is designed to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its research program, GPH102 for the treatment of beta-thalassemia, leverages its gene replacement platform technology by replacing one or both copies of the mutated beta-globin (HBB) gene through HDR to restore HgbA expression to levels. GPH201 is an investigational treatment for X-linked severe combined immunodeficiency syndrome (XSCID), a rare, life-threatening disease where multiple mutations in a single gene (IL2RG) prevent normal immune system function. GPH301 is for the treatment of Gaucher disease. Its pipeline program also includes therapeutic protein production and non-genotoxic conditioning (NGTC).
Company Info
GRAPHITE BIO INC
611 Gateway Blvd, Suite 120
South San Francisco CALIFORNIA US
CEO: Josh Lehrer
Employees: 120
Company Website: https://graphitebio.com/
Phone: 16504840886
GRAPHITE BIO INC / GRPH FAQ
What is the stock price of GRAPHITE BIO INC today?
The current stock price of GRPH is 3.18 USD. The price decreased by -2.75% in the last trading session.
What is the ticker symbol for GRAPHITE BIO INC stock?
The exchange symbol of GRAPHITE BIO INC is GRPH and it is listed on the Nasdaq exchange.
On which exchange is GRPH stock listed?
GRPH stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GRAPHITE BIO INC stock?
6 analysts have analysed GRPH and the average price target is 7.14 USD. This implies a price increase of 124.53% is expected in the next year compared to the current price of 3.18. Check the GRAPHITE BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GRAPHITE BIO INC worth?
GRAPHITE BIO INC (GRPH) has a market capitalization of 184.47M USD. This makes GRPH a Micro Cap stock.
How many employees does GRAPHITE BIO INC have?
GRAPHITE BIO INC (GRPH) currently has 120 employees.
What are the support and resistance levels for GRAPHITE BIO INC (GRPH) stock?
GRAPHITE BIO INC (GRPH) has a support level at 3.06 and a resistance level at 3.34. Check the full technical report for a detailed analysis of GRPH support and resistance levels.
Is GRAPHITE BIO INC (GRPH) expected to grow?
The Revenue of GRAPHITE BIO INC (GRPH) is expected to decline by -100% in the next year. Check the estimates tab for more information on the GRPH EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy GRAPHITE BIO INC (GRPH) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GRPH, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GRPH, evaluating the profitability, health, valuation and growth aspects
- GRAPHITE BIO INC (GRPH) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GRAPHITE BIO INC (GRPH) Sales and EPS estimates to see what analysts future expectations are.
- GRAPHITE BIO INC (GRPH) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GRAPHITE BIO INC (GRPH) Insider and Institutional Ownership to learn about the owners and their transactions.
- GRAPHITE BIO INC (GRPH) Stock Chart to make your own analysis
- GRAPHITE BIO INC (GRPH) Latest news and press-releases to stay up to date.
Does GRAPHITE BIO INC (GRPH) stock pay dividends?
GRPH does not pay a dividend.
What is the Price/Earnings (PE) ratio of GRAPHITE BIO INC (GRPH)?
GRAPHITE BIO INC (GRPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.19).
GRPH Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to GRPH. When comparing the yearly performance of all stocks, GRPH is one of the better performing stocks in the market, outperforming 88.02% of all stocks.
GRPH Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GRPH. No worries on liquidiy or solvency for GRPH as it has an excellent financial health rating, but there are worries on the profitability.
GRPH Financial Highlights
Over the last trailing twelve months GRPH reported a non-GAAP Earnings per Share(EPS) of -2.19. The EPS decreased by -18.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -66.14% | ||
| ROE | -67.9% | ||
| Debt/Equity | 0 |
GRPH Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to GRPH. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 81.37% and a revenue growth -100% for GRPH